Zalifrelimab

Generic Name: Zalifrelimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2148321-69-9

Unique Ingredient Identifier: FE7L22H028

Background: Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Phase 1

Active, not recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Gemcitabine
Drug: Nab paclitaxel
Drug: NLM-001
Drug: Zalifrelimab

First Posted Date: 2021-04-01

Last Posted Date: 2024-12-30

Lead Sponsor: Nelum Corp

Target Recruit Count: 28

Registration Number: NCT04827953

Locations: 🇪🇸
Hospital Universitario Virgen De La Victoria, Málaga, Andalucía, Spain
🇪🇸
Hospital Universitario Miguel Servet, Zaragoza, Aragón, Spain
🇪🇸
Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain

and more 3 locations

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Phase 2

Recruiting

Conditions: Metastatic Soft Tissue Sarcoma
Advanced Soft Tissue Sarcoma

Interventions: Drug: Balstilimab
Drug: Zalifrelimab
Drug: Botensilimab
Drug: Doxorubicin

First Posted Date: 2019-07-22

Last Posted Date: 2024-12-05

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 28

Registration Number: NCT04028063

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy